SB Paxil Social Phobia Study Shows 26% Of Patients "Very Much Improved"
Executive Summary
A European/South African study of SmithKline Beecham's Paxil (paroxetine) in social anxiety disorder/social phobia yielded a rating of "very much improved" for 26% of Paxil patients vs. 9% of placebo patients, as measured by the physician-rated Clinical Global Impression scale.